Activation of oncogenic pathways in idiopathic pulmonary fibrosis

Translational Oncology

Volumn 7, Issue 5, 2014, Pages 650-655

  Stella, Giulia M ^a   Inghilleri, Simona ^a   Pignochino, Ymera ^b   Zorzetto, Michele ^a   Oggionni, Tiberio ^a   Morbini, Patrizia ^a   Luisetti, Maurizio ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EZRIN; MAMMALIAN TARGET OF RAPAMYCIN; MOESIN; RADIXIN; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BIOPSY; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBROBLAST; FIBROSING ALVEOLITIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL PNEUMONIA; MALE; MIDDLE AGED; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VERY ELDERLY;

EID: 84915737608     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.05.002     Document Type: Article

References (35)

1. Vancheri C (2013). Commons pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 22, 265-272.
2. Vogelstein B and Kinzler KW (2004). Cancer genes and the pathways they control. Nat Med 10(8), 789-799.
3. Stella GM, Luisetti M, Pozzi E, and Comoglio PM (2013). Oncogenes in nonsmall- cell lung cancer: emerging connections and novel therapeutic dynamics. Lancet Respir Med 1(3), 251-261.
4. American Thoracic Society, European Respiratory Society (2000). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161, 646-664.
5. Travis WD, Costabel U, Hansell DM, King Jr TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, and Wells AU, et al (2013). An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6), 733-748.
6. Stella GM, Scabini R, Inghilleri S, Cemmi F, Corso S, Pozzi E, Morbini P, Valentini A, Dore R, and Ferrari S, et al (2013). EGFR and KRAS mutational profiling in fresh non-small cell lung cancer (NSCLC) cells. J Cancer Res Clin Oncol 139(8), 1327-1335.
7. Tzouvelekis A, Ntolios P, Karameris A, Vilaras G, Boglou P, Koulelidis A, Archontogeorgis K, Kaltsas K, Zacharis G, and Sarikloglou E, et al (2013). Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int 2013, 654354.
8. PaoWand Chmieleki J (2010). Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 10(11), 760-774.
9. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakawsli MF, Rush VW, Ladanyi M, and Kris MG (2011). Incidence of EGFR exon 19 deletion and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29(15), 2066-2070.
10. Kim MH, Kim HR, Cho BC, Bae MK, Kim EY, Lee CY, Lee JS, Kang DR, and Kim JH (2014). Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibiotrs in lung adenocarcinoma with activating EGFR mutations. Lung Cancer 84(2), 196-202.
11. Oh CK, Murray LA, and Molfino NA (2012). Smoking and idiopathic pulmonary fibrosis. Pulm Med 2012, 808260.
12. Ryu JH, Colby TV, Hartman TE, and Vassallo R (2001). Smoking-related interstitial lung diseases: a concise review. Eur Respir J 17(1), 122-132.
13. Khan EM, Lanir R, Danielson AR, and Goldkorn T (2008). Epidermal growth factor receptor exposed to cigarette smoke is aberrantly activated and undergoes perinuclear trafficking. FASEB J 22(3), 910-917.
14. Filosto S, Becker CR, and Goldkorn T (2012). Cigarette smoke induces aberrant EGFR receptor activation that mediates lung cancer development and resistance to tyrosine kinase inhibitors. Mol Cancer Ther 11(4), 795-804.
15. Tol J, Dijkstra JR, Vink-Börger ME, Nagtegaal ID, Punt CJ, Van Krieken JH, and Ligtenberg MJ (2010).High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell MolMed 14(8), 2122-2131.
16. Weinstein IB (2002). Oncogenic addiction—the Achilles heal of cancer. Science 297(5578), 63-64.
17. Usui K, Ushijima T, Tanaka Y, Tanai C, Noda H, Abe N, Horiuchi H, and Ishihara T (2011). The frequency of epidermal growth factor receptor mutation of nonsmall cell lung cancer according to the underlying pulmonary diseases. Pulm Med 2011, 290132.
18. Fujimoto D, Tomii K, Otoshi T, Kawamura T, Tamai K, Takeshita J, Tanaka K, Matsumoto T, Monden K, and Nagata K, et al (2013). Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer 80(2), 159-164.
19. Sekine A, Tamura K, Satoh H, Tanaka T, Tsunoda Y, Tanaka T, Takoi H, Lin SY, Yatagai Y, and Hashizume T, et al (2013). Prevalence of underlying lung disease in smokers with epidermal growth factor receptor-mutant lung cancer. Oncol Rep 29(5), 2005-2010.
20. Shi L, Tang J, Tong L, and Liu Z (2014). Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83(2), 231-239.
21. Scaltriti M and Baselga J (2006). The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12(18), 5268-5272.
22. Sharma SV, Fischbach MA, Haber DA, and Settleman J (2006). “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12(14 Pt 2), 4392s-4395s.
23. Korfhagen TR, Swantz RJ, Wert SE, McCarty JM, Kerlakian CB, Glasser SW, and Whitsett JA (1994). Respiratory epithelial cell expression of human transforming growth factor-α induces lung fibrosis in transgenic mice. J Clin Invest 93(4), 1691-1699.
24. Vallath S, Hynds RE, Succony L, Janes SM, and Giangreco A (2014). Targeting EGR signaling in chronic lung diseases: therapeutic challenges and opportunities. Eur Resp J [Epub ahead of print].
25. Baker NE and Yu SY (2001). The EGF receptor defines domains of cell cycle progression and survival to regulate cell number in the developing Drosophila eye. Cell 104(5), 699-708.
26. Citri A and Yarden Y (2006). EGF-ERBB signaling: towards the system level. Nat Rev Mol Cell Biol 7(7), 505-516.
27. Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, and Wistuba II (2005). EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res 65(17), 7568-7572.
28. Chilosi M, Zamò A, Doglioni C, Reghellin D, Lestani M, Montagna L, Pedron S, Ennas MG, Cancellieri A, and Murer B, et al (2006). Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir Res 7, 95.
29. Hill R, Song Y, Cardiff RD, and Van Dyke T (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6), 1001-1011.
30. Guertin DA and Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
31. Hebert AM, DuBoff B, Casaletto JB, Gladden AB, and McClatchey AI (2012). Merlin/ERM proteins establish cortical asymmetry and centrosome position. Genes Dev 26, 2709-2723.
32. White ES, Atrasz RG, Hu B, Phan SH, Stambolic V, Mak TW, Hogaboam CM, Flaherty KR, Martinez FJ, and Kontos CD, et al (2006). Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am J Respir Crit Care Med 173, 112-121.
33. Crestani B, Marchand-Adam S, Quesnel C, Plantier L, Borensztajn K, Marchal J, Mailleux A, Soler P, and Dehoux M (2012). Hepatocyte growth factor and lung fibrosis. Proc Am Thorac Soc 9(3), 158-163.
34. Willis BC, duBois RM, and Borok Z (2006). Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3, 377-382.
35. Morbini P, Inghilleri S, Campo I, Oggionni T, Zorzetto M, and Luisetti M (2011). Incomplete expression of epithelial-mesenchymal transition markers in idiopathic pulmonary fibrosis. Pathol Res Pract 207, 559-567.